Therapeutic Solutions International Advances Chronic Obstructive Pulmonary Disease Program by Identifying Novel B Regulatory Cell Mechanism of Action for JadiCell Universal Donor Adult Stem Cell

Rhea-AI Summary

Therapeutic Solutions International (TSOI) has announced a significant advancement in their research on JadiCells for treating Chronic Obstructive Pulmonary Disease (COPD). The company filed a patent demonstrating that the therapeutic effects of JadiCell can be transferred to naïve animals via a unique B cell population. Key findings indicate that depleting these B cells negates the therapeutic impact and that interleukin-35 is crucial for their function. This development bolsters TSOI's intellectual property in respiratory treatments, potentially enhancing their therapeutic applications for both acute and chronic conditions, including COVID-19 ARDS.

Positive

• Filing a patent for JadiCell's therapeutic application in COPD.
• Discovery that B cells can transfer therapeutic effects, suggesting new avenues for treatment.
• Identifying interleukin-35's role could improve future therapeutic strategies.

Negative

• None.

Company Builds on Previous Observations Correlating Clinical Responses to Stem Cells with Unique B Cell Population

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today new data and filing of a patent covering the discovery that JadiCell therapeutic activity in a model of Chronic Obstructive Pulmonary Disease (COPD) can be transferred to naïve animals by a specialized type of B cell. These findings build upon previous discoveries of the company that specialized B cells, called “B regulatory cells”, correlate with patient response to stem cell therapy¹. In a series of experiments the Company found that B cell depletion abrogated therapeutic effects of JadiCell in a COPD model, and that transfer of a unique population of B cells to naïve mice was able to induce a protective effect. Furthermore, antibody mediated blockade of the cytokine interleukin-35, was able to block therapeutic activity.

“Today’s findings provide further scientific basis for clinical use of JadiCells in not only acute pulmonary conditions such as COVID-19 ARDS, but also in more chronic degenerative conditions such as COPD,” said Dr. James Veltmeyer, co-inventor, and Chief Medical Officer of the Company. “By identifying the critical role of interleukin-35 in therapeutic mechanisms, we are one step closer to further increasing the already potent therapeutic effects we observe with these unique cells.”

In addition to the patent licensed from JadiCell, LLC (#9,803,176 B2), for respiratory indications, Therapeutic Solutions International has several patent applications pending and published covering the whole family of umbilical cord mesenchymal stem cells, to which JadiCell belongs to, for treatment of COPD², as well as means of selecting for cells with enhanced activity³.

“The discovery announced today supports not only expansion of our intellectual property portfolio covering this terrible condition, but also adds to the wealth of scientific knowledge which one day will hopefully lead to a cure for COPD,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “We understand that all medical advances sit on the shoulder of other advances, and we are proud to contribute to taking steps towards ending this disease.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

¹ Therapeutic Solutions International Identifies Novel Cellular Marker Associated with Therapeutic Response to JadiCell Stem Cell Treatment
² 20230057957 (uspto.gov)
³ 20230057356 (uspto.gov)

View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005444/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What recent discovery did Therapeutic Solutions International (TSOI) announce regarding JadiCells?

TSOI announced the discovery that JadiCell's therapeutic activity can be transferred to naïve animals through a specialized type of B cell.

How does the new patent affect Therapeutic Solutions International (TSOI)?

The new patent strengthens TSOI's intellectual property portfolio, covering therapeutic uses of JadiCells for treating COPD.

Which cytokine is critical in the therapeutic mechanism of JadiCells according to TSOI?

Interleukin-35 is identified as a critical cytokine in the therapeutic mechanisms of JadiCells.

What implications do these findings have for COPD treatment by TSOI?

The findings support the potential for JadiCells to be used in treating both acute and chronic pulmonary conditions, enhancing clinical applications.